SG Americas Securities LLC Lowers Holdings in BioNTech SE Sponsored ADR $BNTX

SG Americas Securities LLC trimmed its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 26.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 270,245 shares of the company’s stock after selling 95,088 shares during the period. SG Americas Securities LLC’s holdings in BioNTech were worth $24,019,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Dodge & Cox lifted its holdings in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the period. GSK plc acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $84,711,000. BNP Paribas Financial Markets increased its holdings in shares of BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of BioNTech by 344.4% during the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after purchasing an additional 444,332 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in shares of BioNTech in the 4th quarter valued at $41,656,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Performance

BNTX opened at $90.21 on Thursday. The company has a market cap of $22.81 billion, a price-to-earnings ratio of -15.34 and a beta of 1.32. The firm’s fifty day simple moving average is $94.29 and its two-hundred day simple moving average is $98.01. The company has a quick ratio of 8.74, a current ratio of 8.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -5.67 earnings per share for the current fiscal year.

BioNTech announced that its Board of Directors has approved a stock buyback program on Thursday, May 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the transaction, the chief operating officer owned 399,387 shares of the company’s stock, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Wednesday, April 8th. Finally, Bank of America restated a “buy” rating and issued a $128.00 price target on shares of BioNTech in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $129.56.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.